Skip to content
Screener

GeneDx Holdings WGS Accrued Expenses

Accrued Expenses at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$105.92M+92.5%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$34.9M+109%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$181.27M+380%
NeoGenomics logo
NeoGenomicsNEO
$56.27M+15.9%
Azenta logo
AzentaAZTA
$30.97M
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$148.4M-5.7%

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$2.32B-26.9%
Enterprise value$2.32B-26.3%
P/S5.3×-3.5×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001818331-26-000041
Line itemMarch 31, 2026 (Unaudited)December 31, 2025
Current liabilities:
Accounts payable and accrued expenses$46,562$57,645
Short-term lease liabilities5,1294,404
Other current liabilities35,94846,859
Total current liabilities87,639108,908
Long-term debt, net of current portion96,73248,176
Long-term lease liabilities66,33156,046
Other liabilities711,641

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is GeneDx Holdings's accrued expenses?
GeneDx Holdings (WGS) reported accrued expenses of $35.95M in Q1 2026.
How has GeneDx Holdings's accrued expenses changed year-over-year?
GeneDx Holdings's accrued expenses increased by 46.4% year-over-year, from $24.56M to $35.95M.
What is the long-term trend for GeneDx Holdings's accrued expenses?
Over 5 years (2020 to 2025), GeneDx Holdings's accrued expenses has grown at a 10.7% compound annual growth rate (CAGR), from $28.14M to $46.86M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about GeneDx Holdings's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude